These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 21587074

  • 1. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ.
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [Abstract] [Full Text] [Related]

  • 2. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.
    Eur J Pharmacol; 2014 Oct 05; 740():135-43. PubMed ID: 25008069
    [Abstract] [Full Text] [Related]

  • 3. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH, Akhlaghi F.
    Clin Pharmacokinet; 2013 Aug 05; 52(8):615-26. PubMed ID: 23658137
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG, Chen Y, Wang SP, Castro-Perez J, Previs SF, Roddy TP.
    Eur J Pharmacol; 2015 Sep 05; 762():256-62. PubMed ID: 26049012
    [Abstract] [Full Text] [Related]

  • 5. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
    Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C.
    J Lipid Res; 2010 Dec 05; 51(12):3443-54. PubMed ID: 20861162
    [Abstract] [Full Text] [Related]

  • 6. Dalcetrapib: a review of Phase II data.
    Robinson JG.
    Expert Opin Investig Drugs; 2010 Jun 05; 19(6):795-805. PubMed ID: 20465364
    [Abstract] [Full Text] [Related]

  • 7. Update on CETP inhibition.
    Davidson MH.
    J Clin Lipidol; 2010 Jun 05; 4(5):394-8. PubMed ID: 21122682
    [Abstract] [Full Text] [Related]

  • 8. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P, Rye KA.
    Trends Pharmacol Sci; 2011 Dec 05; 32(12):694-9. PubMed ID: 22088767
    [Abstract] [Full Text] [Related]

  • 9. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP.
    Cardiovasc Ther; 2011 Dec 05; 29(6):e89-99. PubMed ID: 20645987
    [Abstract] [Full Text] [Related]

  • 10. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ.
    Curr Opin Lipidol; 2013 Jun 05; 24(3):259-64. PubMed ID: 23652567
    [Abstract] [Full Text] [Related]

  • 11. [HDL and CETP in atherogenesis].
    Pöss J, Böhm M, Laufs U.
    Dtsch Med Wochenschr; 2010 Feb 05; 135(5):188-92. PubMed ID: 20082258
    [Abstract] [Full Text] [Related]

  • 12. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Feb 05; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 13. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ, deGoma EM.
    Annu Rev Med; 2014 Feb 05; 65():385-403. PubMed ID: 24422575
    [Abstract] [Full Text] [Related]

  • 14. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R, Joy TR.
    Cardiovasc Ther; 2011 Oct 05; 29(5):327-39. PubMed ID: 20406242
    [Abstract] [Full Text] [Related]

  • 15. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H.
    Expert Opin Ther Pat; 2009 Sep 05; 19(9):1229-37. PubMed ID: 19663630
    [Abstract] [Full Text] [Related]

  • 16. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR.
    Atherosclerosis; 2018 Nov 05; 278():286-298. PubMed ID: 30347344
    [Abstract] [Full Text] [Related]

  • 17. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
    Miyares MA.
    Ann Pharmacother; 2011 Jan 05; 45(1):84-94. PubMed ID: 21205945
    [Abstract] [Full Text] [Related]

  • 18. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Rhainds D, Arsenault BJ, Brodeur MR, Tardif JC.
    Future Cardiol; 2012 Jul 05; 8(4):513-31. PubMed ID: 22871191
    [Abstract] [Full Text] [Related]

  • 19. HDL metabolism and CETP inhibition.
    Barkowski RS, Frishman WH.
    Cardiol Rev; 2008 Jul 05; 16(3):154-62. PubMed ID: 18414186
    [Abstract] [Full Text] [Related]

  • 20. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ.
    Drugs; 2012 Mar 05; 72(4):491-507. PubMed ID: 22356288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.